Convicted Pharma Fraudster Seeks Post-Trial Acquittal

Law360, New York (November 11, 2010, 3:01 PM EST) -- A pharmaceutical company CEO convicted last year of fraudulently marketing one of his company’s drugs for a deadly lung disease has asked a judge to consider testimony from a new witness he says will establish his innocence.

Testimony from biostatistics expert Steven N. Goodman will prove that InterMune Inc. CEO Dr. W. Scott Harkonen made a reasonable inference from the statistical evidence that his company’s new drug Actimmune could effectively treat patients suffering from idiopathic pulmonary fibrosis, his attorney Mark Haddad claimed in a motion filed...
To view the full article, register now.